Subscribe
shutterstock-149911907-web
Illustration: xrender / Shutterstock.com
26 March 2014Asia-Pacific

Gilead’s attempt to patent Sovaldi in India opposed

Gilead Sciences has received another challenge to its application to patent its new hepatitis C drug Sovaldi (sofosbuvir) in India.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
Indian Patent Office rejects Sovaldi patent, paves way for generics
16 January 2015   The Indian Patent Office has rejected one of US drug maker Gilead’s patent applications to cover hepatitis C drug Sovaldi (sofosbuvir), in a decision that may decrease the blockbuster’s cost in the country.


Editor's picks

BMS blocks biosimilar version of blockbuster cancer drug in India
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025

Editor's picks

Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

More on this story

Asia
Indian Patent Office rejects Sovaldi patent, paves way for generics
16 January 2015   The Indian Patent Office has rejected one of US drug maker Gilead’s patent applications to cover hepatitis C drug Sovaldi (sofosbuvir), in a decision that may decrease the blockbuster’s cost in the country.

More on this story

Asia
Indian Patent Office rejects Sovaldi patent, paves way for generics
16 January 2015   The Indian Patent Office has rejected one of US drug maker Gilead’s patent applications to cover hepatitis C drug Sovaldi (sofosbuvir), in a decision that may decrease the blockbuster’s cost in the country.

More features

European Patent Office’s G1/25 referral under the microscope
Pfizer loses UK appeal over Moderna Covid-19 vaccine patent
WATCH: UPC update—shaping patent litigation
Bayer’s Xarelto patent struck down by German court
Teva draws line under asthma inhaler feud with US rival
Xanax owner fends off ‘Canvax’ mark in EU
Four-lawyer team joins Cozen O’Connor’s new San Diego office
WATCH: Beyond patents — the evolving role of IP lawyers in life sciences